Expert opinion

Hematologic Malignancies/Opinion

Zuma Trial

By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Kite, a Gilead Company, just released an update from the Zuma 7 trial stating statistically significant overall survival benefit for

March 23, 2023

Melanoma & Skin Cancer/Opinion

Neoadjuvant-Adjuvant or Adjuvant Only Pembrolizumab in Advanced Melanoma

By Dr. Radhika Kulkarni Henry Ford Cancer Institute   On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This

March 20, 2023

Lung Cancer/Opinion

CheckMate-722: Nivolumab plus Chemotherapy versus Chemotherapy in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer with Disease Progression after EGFR Tyrosine Kinase Inhibitors

By Dr. Dipesh Uprety Karmanos Cancer Institute   While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is

March 20, 2023

Lung Cancer/Opinion

De-escalating Therapy in Human Papillomavirus-Related Oropharyngeal Cancer

By Dr. Tarik Hadid Wayne State University   Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that

March 9, 2023

GU Malignancies/Opinion

The CALYPSO Study Tests the Combination of MET and PD-L1 Inhibition in Patients with Advanced Papillary Renal Cancer

By Dr. Inas Abuali Massachusetts General Hospital   There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a

March 7, 2023

Hematologic Malignancies/Opinion

Multicenter Real-World Study Shows Comparable Safety and Efficacy of Ide-Cel in Patients with Relapsed/Refractory Multiple Myeloma

By Dr. Richa Parikh Karmanos Cancer Institute & Dr. Harsh Parmar Hackensack Meridian Health   A multicenter retrospective study, which was conducted at 11 academic centers across the United States, reported a

February 27, 2023

Hematologic Malignancies/Opinion

KRD Maintenance: Another Alternative for Newly Diagnosed Multiple Myeloma?

By Dr. Harsh Parmar Hackensack Meridian Health   In an unplanned interim analysis of an international phase-III trial (ATLAS) by Dytfeld et al., performed across 12 centers in Poland and the US,

February 17, 2023

Hematologic Malignancies/Opinion

FDA Approves Pemigatinib in Patients with Relapsed/Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Finally a Treatment Option for a Challenging Disease

By Dr. Abhishek A. Mangaonkar Mayo Clinic   The phase 2 FIGHT-203 trial (NCT#03011372) studied 28 patients with relapsed/refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement. FGFR1 rearrangement should be suspected in patients who

February 7, 2023

Hematologic Malignancies/Opinion

Chemotherapy Free Ph+ ALL Induction? The Promise of Ponatinib plus Blinatumomab

Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center   Philadelphia positive acute lymphoblastic leukemia treatment has been driven by the combination of tyrosine kinase inhibitors targeting BCR-ABL in conjunction with

January 31, 2023

Hematologic Malignancies/Opinion

AGILE trial—Ivosidenib plus Azacitidine versus Azacitidine in IDH1 Mutated Acute Myeloid Leukemia

Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic   In the phase III AGILE trial reported in the New England Journal of Medicine, Pau

January 31, 2023